Format

Send to

Choose Destination
J Biomed Res. 2014 Sep;28(5):349-59. doi: 10.7555/JBR.28.20140045. Epub 2014 Jul 31.

Heart 'omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database.

Author information

1
Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
2
Centre d'Investigation Clinique Pierre Drouin and U 961, Hypertension and Heart Failure Unit, Institut Lourrain du Coeur et des Vaisseaux, Inserm, Nancy, France.
3
Department of Anesthesiology and Critical Care Medicine, InsermUMR-S942, Hôpital Lariboisière, Université Paris Diderot, Paris, France.
4
Equipe obésité et insuffisance cardiaque, Université UPS, Inserm I2MC, UMR 1048, Toulouse, France.
5
Inserm, U744, CHRU, Lille, France.
6
Department of Cardiology, Medical University Graz, Austria.
7
Cardiovascular Institute, University of Manchester, Manchester, UK.
8
Division of Cardiovascular Sciences, Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain.
9
Heart Failure Unit, St Vincent's University Hospital, University College Dublin, Dublin, Ireland.
10
Department of Cardiology, University of Hull, UK.
11
Department of Cardiology, Maastricht University Medical Centre, Netherlands.
12
Center for Heart Failure Research, Department of Cardiology, Maastricht University, Netherlands.
13
Department of Cardiovascular Research, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.
14
International Center for Circulatory Health, Imperial College London, UK.
15
Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Center, University of Glasgow, Glasgow, UK.
16
London School of Hygiene and Tropical Medicine, London, UK.

Abstract

Heart failure is common in older people and its prevalence is increasing. The Heart 'omics' in AGEing (HOMAGE) project aims to provide a biomarker approach that will improve the early diagnosis of heart failure. A large clinical database, based on (1) prospective population studies or (2) cross-sectional, prospective studies or randomized controlled trials (RCTs) of patients at risk for or with overt cardiovascular disease will be constructed to determine most promising 'omics'-based biomarkers to identify the risk of developing heart failure and/or comorbidities. Population studies, patient cohorts and RCTs are eligible for inclusion in the common database, if they received ethical approval to obtain and share data and have baseline information on cardiovascular risk factors. Currently, the HOMAGE database includes 43,065 subjects, from 20 studies in eight European countries, including healthy subjects from three population studies in France, Belgium and Italy (n  =  7,124), patients with heart failure (n  =  4,312) from four cohorts in the UK, Spain and Switzerland and patients at high risk for cardiovascular disease (n  =  31,629) in 13 cohorts. It is anticipated that more partners will join the consortium and enlarge the pooled data. This large merged database will be a useful resource with which to identify candidate biomarkers that play a role in the mechanism underlying the onset and progression of heart failure.

KEYWORDS:

heart failure; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction; left ventricle; morbidity; mortality; population science

Supplemental Content

Full text links

Icon for Journal of Biomedical Research Icon for PubMed Central
Loading ...
Support Center